SECuRE trial to continue with no modifications to protocol
Filed with ASX · · 7 pages · English
• Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population • With the SECuRE trial continuing to recruit, a total of nine participants who had evaluable data by the 25th of November 2025 were included in the interim assessment by the SRC
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026
- Co-PSMA abstract accepted for oral presentation at EAU
- Positive guidance from the US FDA on Cu-64 SARTATE Phase III
- AGM MD Presentation
- Clarity signs copper-67 Supply Agreement with Nusano
Later from Clarity Pharmaceuticals
- SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting
- Quarterly Activities/Appendix 4C Cash Flow Report
- Co-PSMA abstract released
- Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
- SECuRE trial update
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals